Targeted delivery of immunosuppressive agents to the graft endothelium forthe prevention of rejection in lung transplantation

Project Abstract
Lung transplantation (LTx) remains the only available treatment for patients with end-stage pulmonary disease.
Yet, outcomes after LTx are worse compared to the transplant of other solid organs (SOT). Immunosuppressive
regimes used in LTx have been derived from experiences with other SOTs. Yet, such a strategy may be flawed,
as recent data has demonstrated clear differences in the immune responses in the lung. Unlike other SOTs
where initiation of rejection depends on cell trafficking to graft-draining lymphoid organs, in the lung lymphocyte
priming occurs in the lung graft itself. There is thus an urgent need to develop novel approaches to improve
LTx survival. As most lungs transplanted into recipients are harvested from brain dead (BD) donors, there are
important biological consequences that must be considered, particularly the massive inflammatory activity and
cytokine release, which results in the activation of a panoply of cell types. This includes the upregulation of
cellular adhesion molecules (CAM), in particular VCAM-1 and ICAM-1, priming the graft for rejection. Ischemia-
reperfusion injury caused by the transplant procedure has the potential to drive this CAM activation higher. We
thus propose to investigate a novel bi-functional approach to the prevention of LTX rejection, focused on the
development of nanoagents with the potential to block CAM-based priming of the graft concomitant with the
delivery of immunosuppressives. Specifically, we will: 1) Identify peptides capable of binding ICAM-1 or VCAM-
1 with the ability to suppress immune cell trafficking and T cell priming; and 2) Investigate advanced bi-functional
nanoagents designed to localize to the lung and inhibit rejection. The overall goal is the validation of a novel
targeted therapeutic regime with the potential to obviate the need for systemic immunosuppression.

Grant Number: 5U01AI170075-04
NIH Institute/Center: NIH
Principal Investigator: Carl Atkinson